Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease

Andrea Pilotto; Marta Parigi; Giulio Bonzi; Beatrice Battaglio; Elisabetta Ferrari; Lorenza Mensi; Alberto Benussi; Salvatore Caratozzolo; Maura Cosseddu; Rosanna Turrone; Silvana Archetti; Nicholas J Ashton; Henrik Zetterberg; Silvia Giliani; Alessandro Padovani

doi:10.3233/JAD-215646

Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease

J Alzheimers Dis. 2022;87(3):991-997. doi: 10.3233/JAD-215646.

Authors

Andrea Pilotto¹, Marta Parigi², Giulio Bonzi¹, Beatrice Battaglio¹, Elisabetta Ferrari¹, Lorenza Mensi¹, Alberto Benussi¹, Salvatore Caratozzolo¹, Maura Cosseddu¹, Rosanna Turrone¹, Silvana Archetti³, Nicholas J Ashton^{4

5

6

7}, Henrik Zetterberg^{4

8

9

10

11}, Silvia Giliani², Alessandro Padovani¹

Affiliations

¹ Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy.
² A. Nocivelli Institute for Molecular Medicine Spedali Civili and Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
³ III Laboratory of Analyses, Brescia Hospital, Brescia, Italy.
⁴ Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
⁵ Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
⁶ King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.
⁷ NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.
⁸ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
⁹ Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
¹⁰ UK Dementia Research Institute at UCL, London, UK.
¹¹ Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.

PMID: 35404280
DOI: 10.3233/JAD-215646

Abstract

Plasma phosphorylated tau species have been recently proposed as peripheral markers of Alzheimer's disease (AD) pathology. In this cross-sectional study including 91 subjects, plasma and cerebrospinal fluid (CSF) p-tau181 and p-tau231 levels were elevated in the early symptomatic stages of AD. Plasma p-tau231 and p-tau181 were strongly related to CSF phosphorylated tau, total tau and amyloid and exhibited a high accuracy-close to CSF p-tau231 and p-tau181-to identify AD already in the early stage of the disease. The findings might support the use as diagnostic and prognostic peripheral AD biomarkers in both research and clinical settings.

Keywords: Alzheimer’s disease; cerebrospinal fluid; phosphorylated-tau; plasma biomarkers.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / cerebrospinal fluid
Amyloid beta-Peptides / cerebrospinal fluid
Biomarkers / cerebrospinal fluid
Cross-Sectional Studies
Humans
Phosphorylation
tau Proteins / cerebrospinal fluid

Substances

Amyloid beta-Peptides
Biomarkers
tau Proteins